The triple "a" syndrome confirmed by molecular analysis: a case report of 7-year-old boy.

F. Iwańczak,R. Śmigiel,A. Blitek,A. Huebner

DOI: https://doi.org/10.1097/00005176-200501000-00016

2005-01-01

Abstract:The triple A syndrome (MIM*231550), known as Allgrove syndrome, is a rare disease characterized by the triad of achalasia, adrenal insufficiency and deficient tear production (alacrima). In most patients, neurologic and dermatological abnormalities (e.g., palmoplantar hyperkeratosis) are associated features. Other symptoms, including short stature, facial dysmorphic features, osteoporosis and microcephaly, indicate that triple A syndrome is in fact a multisystemic disorder (1–3). Progressive neurologic symptoms of triple A syndrome include autonomic and peripheral motor and sensory neuropathy, mental retardation, dementia, dysarthria, cerebellar ataxia and hyperreflexia (4–6). Thus some authors propose that autonomic and other neurologic abnormalities should be considered as an integral feature of triple A syndrome and have suggested the term ‘‘4A syndrome’’ (7–11). The pathogenesis and pathophysiology of this syndrome are obscure. It is supposed that the disease is a result of progressive failure of the autonomic nervous system, particularly of the cholinergic system (12). Recently, Khelif et al. revealed the lack of neuronal NO synthase and fibrosis of the intermuscular plane in the defective cardia of patients with triple A syndrome (13). Using genetic linkage analysis in a large number of families, a locus involved in triple A syndrome was identified on chromosome 12q13 (14,15). The gene affected in patients with triple A syndrome was identified in this locus and called AAAS (16,17). The AAAS gene is mutated in a homozygous or compound heterozygous state in nearly all kindreds with triple A syndrome studied to date (16–19). In the AAAS gene, various mutations have been found, including missense, nonsense, frameshift and splice mutations. The AAAS gene encodes a 546 amino acid protein and is predominantly expressed in endocrine and neuroendocrine tissues as well as in cerebral structures (16,17). Mutations in the AAAS gene can lead to a changed or truncated protein. The AAAS protein, called ALADIN (alacrima-achalasia-adrenal insufficiency neurologic disorder), belongs to the large family of WD-repeat proteins and is a member of the nuclear pore protein complex (NPC) (20). Disease-associated AAAS mutations result in a failure of ALADIN to localize to NPCs, in that the mutant proteins were found predominantly in the cytoplasm (16,21,22).